CONGRESS FOR VOTERS

Catherine Cortez Masto (D-NV)

S.Amdt. 2945

S.Amdt. 2945 · Senate amendment

A Democratic amendment with 1 Republican cosponsor · See the cosponsor

Changes S. 2296 — National Defense Authorization Act for Fiscal Year 2026

Offered

Offered, and not voted on yet. Most amendments never get a vote: the Senate takes up the bill and moves on without them.

Its path through Congress

  1. Introduced
  2. Pending Consideration

What this amendment would do

This amendment aims to combat illicit xylazine by adding it to the Controlled Substances Act.

Purpose and Changes

  • Classification: It adds xylazine, including its salts and isomers, to Schedule III of the Controlled Substances Act.

  • Definitions: It defines an "ultimate user" for xylazine as a person who received the substance from a registered veterinarian or pharmacy and possesses it for animals they own or care for, or for authorized government animal-control and wildlife programs.

  • Operational Adjustments:

    • Manufacturers are not required to pay for security standard capital expenditures.
    • Labeling and distribution logistics requirements are delayed for 1 year.
    • Practitioner registration and recordkeeping requirements are delayed for 60 days.
    • The FDA and DEA must help speed up manufacturer applications.

  • Legal and Oversight Measures:

    • It updates the Arcos Tracking system to include xylazine.
    • The United States Sentencing Commission must review and potentially amend penalties for offenses involving xylazine.
    • The Attorney General must submit two reports to Congress: one within 18 months regarding the prevalence, origin, and diversion of illicit xylazine, and an update report within 4 years.